These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 26982070)
1. [Transdermal estrogen spray in therapy of postmenopausal syndrome]. Fait T Ceska Gynekol; 2016 Jan; 81(1):77-80. PubMed ID: 26982070 [TBL] [Abstract][Full Text] [Related]
2. The use of estradiol metered-dose transdermal spray in clinical practice. Fait T; Fialova A; Pastor Z Climacteric; 2018 Dec; 21(6):549-553. PubMed ID: 30296172 [TBL] [Abstract][Full Text] [Related]
4. Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms. Mizunuma H Climacteric; 2011 Oct; 14(5):581-9. PubMed ID: 21848497 [TBL] [Abstract][Full Text] [Related]
5. Comparison of efficacy and local tolerability of estradiol metered-dose transdermal spray to estradiol patch in a network meta-analysis. Kovács G; Zelei T; Vokó Z Climacteric; 2016 Oct; 19(5):488-95. PubMed ID: 27593417 [TBL] [Abstract][Full Text] [Related]
6. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study. De Aloysio D; Rovati LC; Giacovelli G; Setnikar I; Bottiglioni F Arzneimittelforschung; 2000 Mar; 50(3):293-300. PubMed ID: 10758784 [TBL] [Abstract][Full Text] [Related]
7. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids. Rozenberg S; Ylikorkala O; Arrenbrecht S Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Alora Study Group. Good WR; John VA; Ramirez M; Higgins JE Climacteric; 1999 Mar; 2(1):29-36. PubMed ID: 11915854 [TBL] [Abstract][Full Text] [Related]
9. Use of a new transdermal delivery system for estrogen replacement therapy in postmenopausal women. Figueroa-Casas PR; Alfonsin A; Arrighi A; Bluvstein G; Del Castillo R; Goldsman T; Inglesi J; Itala J; Novelli J; Monti C Maturitas; 1994 Dec; 20(2-3):139-44. PubMed ID: 7715465 [TBL] [Abstract][Full Text] [Related]
10. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years. Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K Menopause; 2006; 13(1):130-8. PubMed ID: 16607109 [TBL] [Abstract][Full Text] [Related]
11. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial. Buster JE; Koltun WD; Pascual ML; Day WW; Peterson C Obstet Gynecol; 2008 Jun; 111(6):1343-51. PubMed ID: 18515518 [TBL] [Abstract][Full Text] [Related]
12. Aerodiol versus the transdermal route: perspectives for patient preference. Lopes P; Rozenberg S; Graaf J; Fernandez-Villoria E; Marianowski L Maturitas; 2001 Jun; 38 Suppl 1():S31-9. PubMed ID: 11390122 [TBL] [Abstract][Full Text] [Related]
13. [Transdermal estradiol--the possibility for replacement therapy in the postmenopause]. Rachev E Akush Ginekol (Sofiia); 1994; 33(3):45-7. PubMed ID: 7793531 [TBL] [Abstract][Full Text] [Related]
15. [Comparison of transdermal with oral hormone substitution: a multicenter study with a new matrix patch]. Sajtos B; Herold J; Winkler UH; Schindler AE Zentralbl Gynakol; 1995; 117(10):524-30. PubMed ID: 7491835 [TBL] [Abstract][Full Text] [Related]